CTI Will File sNDA For Zevalin In Follicular Lymphoma, CEO Bianco Tells DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
Improvement in progression-free survival is seen in patients with advanced follicular lymphoma following treatment with Zevalin.
You may also be interested in...
Bayer Schering Gets Positive European Review For Zevalin In Follicular Lymphoma
CTI anticipates second-half filing in the U.S., CEO Bianco tells “The Pink Sheet” DAILY.
Bayer Schering Gets Positive European Review For Zevalin In Follicular Lymphoma
CTI anticipates second-half filing in the U.S., CEO Bianco tells “The Pink Sheet” DAILY.
Cell Therapeutics Cuts Expenses As It Transforms Into Commercial Operation
CTI will reduce development staff as it shores up its commercial team ahead of Zevalin launch.